here's a potential little gem for you myriad of guys and gals who like "diddy" companies ...... preliminary 12 month results to 30/11/06 due Tuesday 28 Feb.



Founded: November 2003
Ownership: Publicly traded on AiM of London Stock Exchange
Personnel: 25

Revenues:
Proximagen provides highly specialized laboratory services for pharmaceutical and biotech companies to support the discovery and development of novel therapeutic approaches to neurological disorders. Proximagen's personnel have particular expertise in neurodegenerative conditions, including Parkinson's disease and Alzheimer's disease.

Profile:
Proximagen is a neuroscience research company focused on drug development for neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease.


The shares are tightly held, so don't expect to be able to trade in "swathes" ...... maximum is probably only 2500/5000.

red = 50 dma
green = 200 dma

would have posted the potted stuff you can find by logging onto the quote page, but don't know how to.

help anyone?

well the good news has taken a little while to arrive, but here it is!

Proximagen Neuroscience PLC confirmed it received takeover approaches from a number of parties and said that the talks are at a relatively early stage, with no certainty that any of them will result in a formal offer.

would i ever lead you guys (n gals) astray?
of course i would, though not intentionally.

so next Q is will my other diddy-minnow BML also come good in the next 2/3 months?
i suspect so, but we shall have to wait and see

This one looks to be in a downtrend, with the only saving factor being a possible takeover? Money to be made on that for sure, but if that doesn't happen, PRX looks to be unattractive (shorting excepted).

Rumour of 50m-fundraising appears to be true (see RNS) - but what I don't understand is why the City ( and Punters) would back this company in preference to one with a revenue-stream . . . . . . it's not as though they have a lot of successes to date . . . or, maybe am I missing something?

Buy recommendation fmro Growth Company Investor

http://www.growthcompany.co.uk/recommendations/1052547/proximagen-neuroscience.thtml

it has been suggested that it is time to dust this one off

You need your head tested to buy these

http://www.moneyam.com/action/news/showArticle?id=4424929

aldwickk - 05 Jan 2011 17:02 - 10 of 11
You need your head tested to buy these

I dont think so, doing very well in 2012.

USL Pharma International close to acquiring Proximagen Group
StockMarketWire.com
USL Pharma International's recommended offer for Proximagen Group looks likely to go ahead.

The High Court has made an order confirming the reduction of capital in connection with the scheme by which USL is implementing the acquisition.

Proximagen has made an application to the London Stock Exchange for the cancellation of the admission to trading of its shares on AIM effective from 7.00 a.m. tomorrow